Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | PGR | P06401 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | BTN3A1 | O00481 | 6/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | OGG1 | O15527 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28401524 | 0.91 | BTN3A1 (0.41) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL20845948 | 0.91 | BTN3A1 (0.41) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL29692333 | 0.91 | BTN3A1 (0.41) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL30435963 | 0.91 | BTN3A1 (0.41) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL29895522 | 0.90 | BTN3A1 (0.41) | ALDH1A1BTN3A1KDM4EOGG1HTT | |
| SCHEMBL28986476 | 0.90 | BTN3A1 (0.41) | ALDH1A1BTN3A1KDM4EOGG1HTT | |
| SCHEMBL21192831 | 0.90 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL20840403 | 0.90 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL23827926 | 0.90 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1PGRGAA | |
| SCHEMBL28529771 | 0.90 | ALDH1A1 (0.39) | MEN1KMT2AALDH1A1PGRGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2026-05-26 | — | — | US | disclosed |
| EP-4021912-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2022-07-06 | — | — | EP | disclosed |
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-18 | — | — | US | disclosed |
| WO-2021035360-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | Risen (Suzhou) Pharma Tech Co., Ltd. (CN) | 2021-03-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210078970-A1 | PRODRUGS OF THE TYROSINE KINASE INHIBITOR FOR TREATING CANCER | ABL1, FLT3, SRC | MEN1 1705/4885KMT2A 1351/4885ALDH1A1 866/4885 |
| US-12637441-B2 | Prodrugs of the tyrosine kinase inhibitor for treating cancer | EGFR, ERBB2, MET | MEN1 2789/4885KMT2A 1094/4885ALDH1A1 3172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.